Tolvaptan: A New Weapon for a Tough Kidney Disease

This F1000 commentary reports on a study whose findings support the use of tolvaptan to slow the progression of autosomal dominant polycystic kidney disease (ADPKD).

Source: Medscape Nephrology Podcast - February 14, 2013 Category: Urology & Nephrology Authors: Medscape Source Type: podcasts